Edition:
United States

Adocia SA (ADOC.PA)

ADOC.PA on Paris Stock Exchange

18.70EUR
9:28am EDT
Change (% chg)

€0.03 (+0.16%)
Prev Close
€18.67
Open
€18.68
Day's High
€18.84
Day's Low
€18.62
Volume
11,489
Avg. Vol
53,685
52-wk High
€65.45
52-wk Low
€18.05

Latest Key Developments (Source: Significant Developments)

Adocia FY net result turns to loss of 7.9 million euros
Tuesday, 7 Mar 2017 12:00pm EST 

Adocia SA : Financial results for 2016 and its perspectives for 2017 . FY net loss 7.9 million euros ($8.36 million) versus profit 12.6 million euros year ago . Regarding BioChaperone Combo co is currently preparing first dose-response study in people with type 1 diabetes . Regarding BioChaperone Combo expects to launch second outpatient repeated administration study in people with type 2 diabetes during Q4 2017 . Regarding new programs objective is to initiate first-in-man studies for BioChaperone Glucagon and one BioChaperone Glargine GLP-1 product before end of year .Early in 2017 co announced initiation of two new multi-hormonal combination projects for treatment of type 1 diabetes; aims to initiate first clinical study during Q4 2017.  Full Article

Adocia says Eli Lilly terminates collaboration biochaperone Lispro
Friday, 27 Jan 2017 01:30am EST 

Adocia SA : Adocia announces termination by Eli Lilly of collaboration on biochaperone Lispro .As a consequence of such decision and according to terms of this agreement, rights that Adocia has licensed to Lilly will revert to Adocia at no cost.  Full Article

Adocia Q3 revenue rises to 6.5 million euros
Wednesday, 12 Oct 2016 12:00pm EDT 

Adocia SA : Revenue of 6.5 million euros for Q3, compared to 6.2 million euros in 2015 .Cash position of 57.5 million euros at Sept. 30, 2016.  Full Article

Adocia H1 net income turns to loss of 4.2 million euros
Wednesday, 20 Jul 2016 12:00pm EDT 

Adocia SA : H1 revenue of 11.9 million euros ($13.1 million) versus 12.7 million euros year ago . H1 operating loss of 4.2 million euros versus profit of 4.8 million euros year ago . H1 net loss of 4.2 million euros versus profit of 6.7 million euros year ago .Cash position as of June 30 of 60.9 million euros compared to 72.1 million euros as of January 1st.  Full Article

Adocia, Lilly announce positive results from BioChaperone Lispro U100 study
Tuesday, 31 May 2016 12:00pm EDT 

Eli Lilly And Co : Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin biochaperone lispro U100 in healthy Japanese subjects .Both BioChaperone Lispro and Humalog were similarly well tolerated; no new or unexpected safety findings were observed..  Full Article

Adocia and Lilly announce positive results from Phase 1b study of Lispro U100
Wednesday, 27 Apr 2016 12:00pm EDT 

Adocia SAS:Adocia and Lilly announce positive results from a Phase 1b study of repeated administration of ultra-rapid biochaperone Lispro U100 in people with type 2 diabetes.  Full Article

Adocia initiates phase 1/2 clinical trial on post-meal effect of rapid-acting human insulin
Monday, 11 Apr 2016 12:00pm EDT 

Adocia SAS:Initiates a phase 1/2 clinical trial on the post-meal effect of rapid-acting human insulin, HinsBet U100.  Full Article

Adocia to be removed from the SBF 120 index
Wednesday, 9 Mar 2016 07:00pm EST 

Euronext NV:Announces the quarterly review of the CAC family indices.Sodexo to be included in the CAC 40 index.Alstom to be removed from the CAC 40 index.Alstom and Eutelsat Communications to be included in the CAC Next 20 index.Sodexo and Edenred to be removed from the CAC Next 20 index.Eutelsat Communications to be included in the CAC Large 60 index.Edenred to be excluded from the CAC Large 60 index.Edenred, Amundi, Worldline and Spie to be included in the CAC Mid 60 index.Eutelsat, Adocia and Coface to be removed from the CAC Mid 60 index.Amundi, Worldline and Spie to be included in the SBF 120 index.Adocia and Coface to be removed from the SBF 120 index.Adocia, Coface, Showroomprive, Store Electronics and Constructions Industrielles Mediterranee to be included in the CAC small index.Spie and Worldline to be removed from the CAC small index.Amundi, Edenred, Showroomprive, Store Electronics and Constructions Industrielles Mediterranee to be included in the CAC Mid & Small index.Eutelsat to be removed from the CAC Mid & Small index.Amundi, Showroomprive, Store Electronics and Constructions Industrielles Mediterranee to be included in the CAC All-Tradable index.Changes will be effective as of March 21, 2016.  Full Article

Adocia and Lilly initiate phase 1b study evaluating Lispro U100
Friday, 29 Jan 2016 01:30am EST 

Adocia SAS:Adocia and Eli Lilly and Co initiate phase 1b study evaluating ultra-rapid insulin biochaperone Lispro U100 in healthy Japanese subjects.  Full Article

Adocia and Lilly report positive results of study on BioChaperone Lispro U200
Thursday, 10 Dec 2015 07:00pm EST 

Adocia SAS:Announces the successful completion of a preliminary Phase 1 clinical trial evaluating BioChaperone Lispro U200, a concentrated formulation of BioChaperone Lispro, the ultra-rapid formulation of insulin lispro licensed to Lilly.Adocia receives a $10 million milestone payment from Lilly after successful completion of this clinical pilot study.BioChaperone Lispro U200, a BioChaperone Lispro formulation at twice the standard insulin concentration, met all pre-specified endpoints, delivering an ultra-rapid profile equivalent to BioChaperone Lispro U100 in an initial pilot study.  Full Article

More From Around the Web

BRIEF-Adocia FY net result turns to loss of 7.9 million euros

* FY net loss 7.9 million euros ($8.36 million) versus profit 12.6 million euros year ago